Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
600222 Henan Taloph Pharmaceutical Stock
6.220
-0.050-0.80%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Operating Cash Flow
Goods sale service render cash
1.44% 1.19B 3.09% 754.32M 15.22% 355.72M 16.06% 1.63B
Refunds of taxes and levies
-- 556.9K -- 556.9K -- -- -- --
Cash received relating to other operating activities
59.91% 25.59M -2.33% 13.66M 135.62% 8.16M -49.34% 28.53M
Cash inflows from operating activities
2.27% 1.22B 3.06% 768.53M 16.56% 363.89M 13.53% 1.66B
Goods services cash paid
12.32% 821.04M 6.83% 529.35M 41.62% 294.81M 11.40% 1.04B
Staff behalf paid
24.75% 249.05M 18.74% 163.81M 13.91% 84.93M 30.78% 285.71M
All taxes paid
21.39% 46.6M 45.20% 37.41M 29.31% 21.84M 2.28% 51M
Cash paid relating to other operating activities
9.58% 176.16M 31.94% 104.35M 103.73% 114.27M -1.84% 181.63M
Cash outflows from operating activities
14.43% 1.29B 13.08% 834.91M 45.02% 515.86M 12.36% 1.56B
Net cash flows from operating activities
-215.85% -72.99M -1,000.19% -66.38M -249.20% -151.97M 35.72% 99.66M
Investing cash flow
Cash received from disposal of investments
117.33% 1.17B 214.30% 1.11B 263.70% 591.26M -51.79% 717.81M
Cash received from returns on investments
903.59% 28.53M 175.97% 2.15M 51.37% 374.81K 46.54% 3.07M
Net cash received from disposal of fix assets、 intangible assets 、other long-term asset
-71.75% 178.39K -98.78% 7.7K -- 2K -20.09% 63.35K
Net cash received from disposal of subsidiaries and other business units
-- 200K -- -- -- -- -- 570K
Cash received relating to other investing activities
-- -- -- -- -- -- 1,171.48% 22.89M
Cash inflows from investing activities
112.30% 1.2B 194.56% 1.11B 263.38% 591.64M -50.14% 744.4M
Cash paid to acquire fixed assets intangible assets and other long-term assets
-1.41% 28.66M 43.64% 22.29M 60.51% 8.53M -46.22% 39.07M
Cash paid to acquire investments
79.30% 1.02B 197.22% 972.9M 293.34% 520M -49.94% 805.48M
Cash outflows from investing activities
75.38% 1.05B 190.27% 995.19M 284.34% 528.53M -49.78% 844.55M
Net cash flows from investing activities
533.50% 148.27M 239.00% 112.05M 149.43% 63.11M 46.97% -100.16M
Financing cash flow
Cash received from capital contributions
-- -- -- -- -- -- -99.92% 100K
-Including: Cash received from capital contributions by minority shareholders of subsidiaries
-- -- -- -- -- -- -99.92% 100K
Cash from borrowing
-14.52% 447.9M -62.61% 113.9M -62.19% 43.4M 8.98% 1.12B
Cash received relating to other financing activities
336.18% 798.24M 758.88% 599.31M 16.72% 58.8M 170.10% 269.87M
Cash inflows from financing activities
76.26% 1.25B 90.51% 713.2M -38.12% 102.2M 10.48% 1.39B
Borrowing repayment
79.19% 1.02B 65.20% 778.13M -23.04% 94.31M 51.72% 1.29B
Dividend interest payment
-33.05% 42.93M -11.05% 33.25M -9.65% 16.27M 29.16% 84.56M
Cash payments relating to other financing activities
393.80% 275.49M 350.32% 172.57M -- 18.87M 28.52% 171.9M
Cash outflows from financing activities
94.26% 1.33B 79.97% 983.96M -7.90% 129.45M 47.37% 1.55B
Net cash flows from financing activities
-538.68% -88.2M -57.10% -270.75M -210.85% -27.26M -174.71% -156.58M
Net cash flow
Net increase in cash and cash equivalents
-126.41% -12.91M -70.62% -225.09M -1,923.20% -116.12M -266.84% -157.08M
Add:Begin period cash and cash equivalents
-32.23% 330.24M -32.23% 330.24M -32.23% 330.24M 23.95% 487.32M
End period cash equivalent
-40.82% 317.32M -70.41% 105.15M -56.63% 214.11M -32.23% 330.24M
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions
------Unqualified opinion
Auditor
------Beijing Xinghua Certified Public Accountants (Special General Partnership)

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company is a limited company approved by the Henan Economic System Reform Commission (1998) No. 38, with Zhengzhou Zhongsheng Industrial Group Co., Ltd. as the main sponsor, and co-sponsored by five companies including Henan Zhiyi Investment and Development Co., Ltd., Zhengzhou Zhulin Xianzhu Washing Products Co., Ltd., Zhengzhou Zhulin Refractory Materials Company, and Gongyi Zhulin Xinhua Packaging Materials Factory. Approved by the China Securities Regulatory Commission Securities Regulatory Commission, issue letter No. 98 [1999]. On August 13, 1999, the Japanese company issued 35 million public shares. The total share capital after issuance was 13,6145.24 million yuan. The company's main business is pharmaceutical manufacturing and drug research and development services, which specifically include the four segments of pharmaceutical preparation, traditional Chinese medicine tablets, drug research and development services, and pharmaceutical material distribution. The company's pharmaceutical business is mainly based on oral formulations of traditional Chinese medicines. The treatment areas cover respiratory, cardiovascular, digestive, neurological and gynecological diseases. The main products include Shuanghuanglian Oral Liquid series, Shuangjin conjugate, salvia oral liquid, pediatric fever and cough relief liquid, pediatric compound chicken chewable tablets, shavelin tablets, etc. Among them, Shuanghuanglian Oral Liquid (concentrated type), Shuanghuanglian Oral Liquid (children's type), Shuangjin Combinant, and Pediatric Compound Chicken Chewables are exclusive products of the company. Corporate honors: The Pharmaceutical Chamber of Commerce of the All-China Federation of Industry and Commerce awarded the company the honor of “anti-epidemic, charity and love”, high-tech enterprises in Henan Province, “National High-tech Industrialization Demonstration Project”, “Excellent Enterprise in Zhengzhou”, etc.
CEO: --
Market: --
Listing Date: 11/05/1999
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist